Passa al contenuto
Merck

FN-EDA mediates angiogenesis of hepatic fibrosis via integrin-VEGFR2 in a CD63 synergetic manner.

Cell death discovery (2020-12-10)
Xiaonan Su, Xiaowen Ma, Xiaoyu Xie, Hao Wu, Le Wang, Yuemin Feng, Zhen Yu, Chenxi Liu, Jianni Qi, Qiang Zhu
ABSTRACT

Pathological angiogenesis is an important component of hepatic fibrosis along with fibrous deposition, but its role is not well understood. Here, we demonstrated that fibronectin containing extra domain A(FN-EDA), a fibronectin splice variant highly expressed in hepatic fibrosis, mediated angiogenesis in disease progression. FN-EDA was positively correlated with pathological angiogenesis in hepatic fibrosis, and a reduction in FN-EDA expression was associated with diminished intrahepatic angiogenesis and fibrosis. FN-EDA mostly colocalized with hepatic stellate cells (HSCs) and interference or blockage of FN-EDA attenuated migration and tube formation in co-cultured endothelial cells. Mechanistic studies indicated that FN-EDA was secreted to promote phosphorylation of VEGFR2 with the assistance of integrin and CD63. Targeting FN-EDA-integrin combination postponed the progression of hepatic angiogenesis and fibrosis in vivo. These results indicated that FN-EDA plays an emerging role in angiogenesis in hepatic fibrosis and could be a potential therapeutic intervention for the disease.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fibronectina, recombinant, expressed in HEK 293 cells, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Monoclonal Anti-Fibronectin, Cellular antibody produced in mouse, clone FN-3E2, ascites fluid
Sigma-Aldrich
Fibronectina, lyophilized powder, suitable for cell culture